|Bid||29.40 x 300000|
|Ask||29.60 x 300000|
|Day's range||29.40 - 29.40|
|52-week range||29.20 - 71.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Breakthrough Alzheimer’s treatments that remove toxic proteins from the brain have revived interest in vaccines to treat the memory-robbing disease, potentially offering a cheaper, easy-to-administer option for millions of people, according to interviews with 10 scientists and company executives. Clinical trials are underway or completed for at least seven Alzheimer’s vaccines designed to harness the immune system to rid the brain of the disease-related proteins beta amyloid or tau, a review of the U.S. government’s ClinicalTrials.gov database found. The renewed interest in Alzheimer's vaccines follows a promising first attempt more than 20 years ago that was abandoned after 6% of study volunteers developed life-threatening brain inflammation known as meningoencephalitis.
Prothena (PRTA) makes good progress with its AD candidates. However, AD is a challenging space and the successful development of these candidates is crucial.
Prothena (PRTA) delivers earnings of 38 cents in the third quarter, driven by the license and option exercise fee paid by BMY.